Randomized, Open-label Economic and Medical Study on the Lymph Node Management of Squamous Cell Carcinoma of the Oral Cavity and Oropharynx Tumor Stage 1 or 2, Nodes 0 (T1-T2 N0) Operable (SentiMERORL)
Primary Purpose
Head and Neck Tumors
Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Surgery: GS strategy
Surgery: Classic strategy
Sponsored by
About this trial
This is an interventional treatment trial for Head and Neck Tumors focused on measuring Squamous carcinoma of oral cavity and oropharynx, Sentinel lymph node, Lymph node dissection, Equivalence
Eligibility Criteria
Inclusion criteria:
- Man or woman age over 18 without upper age limit
- Social Insured
- Patient Information and Informed Consent signed by the patient
- Patient not participating in another trial since the legal time
- Absence of any previous treatment for cancer of the Upper AeroDigestive Tract (VADS)
- Patient with primary squamous cell carcinoma of the oral cavity or oropharynx documented by biopsy with histopathologic analysis not older than 1 month
- curable or operable tumor with radiation under the Tumor, Nodes, Metastasis (TNM) stage, location and the patient's general condition
- Stage T1 and T2
- Tumor listed N0 satisfying the following conditions (21 days validity period): A) absence of lymphadenopathy palpable on clinical examination of the ENT investigator. B) CT scan or MRI with injection of contrast product: lack of suspicious adenomegaly for metastasis = node size less than one centimeter and 1.5 cm for the group IIa, ovoid, homogeneous, not taking contrast and showing no signs of lymph perinodal invasion ( hyperdensity fat, vascular adhesion), absence of lymph node group (> 3)
- Systematic ENT endoscopy eliminating a second synchronous tumor and precisely establishing the T (21 days validity period)
- Absence of metastasis: M0
Exclusion criteria:
- Failure of one of the inclusion criteria
- Other cancer being treated
- Non-invasive tumor: high-grade dysplasia, carcinoma in situ
- Inadequate tumor excision: margins invaded without further recovery in safe zone
- Contraindications to surgery such sentinel node or lymph node dissection
- Contraindications to radiotherapy
Contraindications to performing a scan:
- Known allergy or intolerance to the injected product and particularly with Technetium-99
- Pregnancy
- Refusal to accept the full treatment regardless of the strategy
- Follow-up not possible
- Refusal to accept the described follow-up and / or provide the necessary information for the study
- Patient already treated for the tumor outside an excision biopsy
- Patient who previously had chemotherapy or immunotherapy for another cancer outside VADS within less than 6 months
- Patient undergoing cervical or VADS radiotherapy whatever the cause or time
- Patient who have had cervical spine surgery regardless of the cause or time
Sites / Locations
- Montpellier University Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Other
Arm Label
GS strategy
Classic strategy
Arm Description
sentinel node biopsy
systematic lymphadenectomy
Outcomes
Primary Outcome Measures
Nodal recurrence rate
The absence of recurrence at 2 years will be affirmed by the absence of clinical signs confirmed by a medical imaging exam.
Secondary Outcome Measures
Evaluation of quality of life with Head and Neck 35 (H&N35)
Evaluate quality of life on the two years of the follow up
Evaluation of the costs
The costs will be collected Under usual forms as the direct, indirect and intangible costs, directly to the relevant services and patients themselves
Evaluation of quality of life with Quality of Life Questionnaire Core 30 (QLQ-C30)
Evaluate quality of life on the two years of the follow up
Evaluation of quality of life with EuroQOL 5D (EQ 5D)
Evaluate quality of life on the two years of the follow up
Evaluation of quality of life with Short Form 36 (SF36))
Evaluate quality of life on the two years of the follow up
Full Information
NCT ID
NCT02855723
First Posted
July 19, 2016
Last Updated
August 1, 2016
Sponsor
University Hospital, Montpellier
1. Study Identification
Unique Protocol Identification Number
NCT02855723
Brief Title
Randomized, Open-label Economic and Medical Study on the Lymph Node Management of Squamous Cell Carcinoma of the Oral Cavity and Oropharynx Tumor Stage 1 or 2, Nodes 0 (T1-T2 N0) Operable
Acronym
SentiMERORL
Official Title
Randomized, Open-label Economic and Medical Study on the Lymph Node Management of Squamous Cell Carcinoma of the Oral Cavity and Oropharynx T1-T2N0 Operable : Comparison of the Reference Strategy Based on a the Systematic Lymph Node Dissection Versus the Strategy Based on the Technique of Sentinel Lymph Node.
Study Type
Interventional
2. Study Status
Record Verification Date
July 2016
Overall Recruitment Status
Completed
Study Start Date
April 2008 (undefined)
Primary Completion Date
August 2015 (Actual)
Study Completion Date
August 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Montpellier
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Currently, patients with cancer of oral cavity or oropharynx T1-T2N0 classified, are treated surgically with systematic lymph node dissection while in 70%, there is no lymph node metastasis. The technique of identifying the sentinel node (GS) is validated for these tumors because the status of the sentinel node is predictive of the other nodes status in the neck. This helps to diagnose the presence of metastases without lymph node dissection and thus select patients requiring a treatment node. However, the oncological and functional results of a therapeutic strategy based on identifying the GS is unknown.
This open-label randomized multicenter clinical trial aims to compare the oncologic and functional outcome of two strategies : the current management versus the management based on the sentinel lymph node.
The hypothesis is based on a nodal control difference at 2 years in both arms not exceeding 10%. The medico-economic analysis will be conducted in two stages : a classic stage on 2 years with estimated incremental cost-effectiveness and incremental cost-utility, then a step with log term modeling.
A reduction in morbidity and treatment costs in the sentinel node arm are expected in this study.
Detailed Description
This study schedules the screening visit (V0) and then 9 follow-up visits during 24 months.
At the screening, after verification of the eligibility criteria and signature of the informed consent form, the subject will be randomized in one of 2 arms. At the inclusion the following exams have to be done : clinical exam, panendoscopy, cytologic and histologic analysis and CT-Scan (or MRI). For each visit, the investigator will perform a clinical exam and the subjects should complete some questionnaires themselves from V0 to V3, V6 (12 months) and V9. At the last visit (24 months) the patients will have a CTC-Scan ou MRI.
At the end of the follow-up period (24 months), the data of subjects survival will be recorded during three years.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Head and Neck Tumors
Keywords
Squamous carcinoma of oral cavity and oropharynx, Sentinel lymph node, Lymph node dissection, Equivalence
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
307 (Actual)
8. Arms, Groups, and Interventions
Arm Title
GS strategy
Arm Type
Active Comparator
Arm Description
sentinel node biopsy
Arm Title
Classic strategy
Arm Type
Other
Arm Description
systematic lymphadenectomy
Intervention Type
Other
Intervention Name(s)
Surgery: GS strategy
Intervention Description
sentinel node biopsy
Intervention Type
Other
Intervention Name(s)
Surgery: Classic strategy
Intervention Description
systematic lymphadenectomy
Primary Outcome Measure Information:
Title
Nodal recurrence rate
Description
The absence of recurrence at 2 years will be affirmed by the absence of clinical signs confirmed by a medical imaging exam.
Time Frame
24 months after the surgery
Secondary Outcome Measure Information:
Title
Evaluation of quality of life with Head and Neck 35 (H&N35)
Description
Evaluate quality of life on the two years of the follow up
Time Frame
At the inclusion, and at 2, 4, 6, 12 and 24 months after the surgery
Title
Evaluation of the costs
Description
The costs will be collected Under usual forms as the direct, indirect and intangible costs, directly to the relevant services and patients themselves
Time Frame
At the inclusion, and at 2, 4, 6, 8, 10, 12 16, 20 and 24 months after the surgery
Title
Evaluation of quality of life with Quality of Life Questionnaire Core 30 (QLQ-C30)
Description
Evaluate quality of life on the two years of the follow up
Time Frame
At the inclusion, and at 2, 4, 6, 12 and 24 months after the surgery
Title
Evaluation of quality of life with EuroQOL 5D (EQ 5D)
Description
Evaluate quality of life on the two years of the follow up
Time Frame
At the inclusion, and at 2, 4, 6, 12 and 24 months after the surgery
Title
Evaluation of quality of life with Short Form 36 (SF36))
Description
Evaluate quality of life on the two years of the follow up
Time Frame
At the inclusion, and at 2, 4, 6, 12 and 24 months after the surgery
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria:
Man or woman age over 18 without upper age limit
Social Insured
Patient Information and Informed Consent signed by the patient
Patient not participating in another trial since the legal time
Absence of any previous treatment for cancer of the Upper AeroDigestive Tract (VADS)
Patient with primary squamous cell carcinoma of the oral cavity or oropharynx documented by biopsy with histopathologic analysis not older than 1 month
curable or operable tumor with radiation under the Tumor, Nodes, Metastasis (TNM) stage, location and the patient's general condition
Stage T1 and T2
Tumor listed N0 satisfying the following conditions (21 days validity period): A) absence of lymphadenopathy palpable on clinical examination of the ENT investigator. B) CT scan or MRI with injection of contrast product: lack of suspicious adenomegaly for metastasis = node size less than one centimeter and 1.5 cm for the group IIa, ovoid, homogeneous, not taking contrast and showing no signs of lymph perinodal invasion ( hyperdensity fat, vascular adhesion), absence of lymph node group (> 3)
Systematic ENT endoscopy eliminating a second synchronous tumor and precisely establishing the T (21 days validity period)
Absence of metastasis: M0
Exclusion criteria:
Failure of one of the inclusion criteria
Other cancer being treated
Non-invasive tumor: high-grade dysplasia, carcinoma in situ
Inadequate tumor excision: margins invaded without further recovery in safe zone
Contraindications to surgery such sentinel node or lymph node dissection
Contraindications to radiotherapy
Contraindications to performing a scan:
Known allergy or intolerance to the injected product and particularly with Technetium-99
Pregnancy
Refusal to accept the full treatment regardless of the strategy
Follow-up not possible
Refusal to accept the described follow-up and / or provide the necessary information for the study
Patient already treated for the tumor outside an excision biopsy
Patient who previously had chemotherapy or immunotherapy for another cancer outside VADS within less than 6 months
Patient undergoing cervical or VADS radiotherapy whatever the cause or time
Patient who have had cervical spine surgery regardless of the cause or time
Facility Information:
Facility Name
Montpellier University Hospital
City
Montpellier
ZIP/Postal Code
34295
Country
France
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
33052754
Citation
Garrel R, Poissonnet G, Moya Plana A, Fakhry N, Dolivet G, Lallemant B, Sarini J, Vergez S, Guelfucci B, Choussy O, Bastit V, Richard F, Costes V, Landais P, Perriard F, Daures JP, de Verbizier D, Favier V, de Boutray M. Equivalence Randomized Trial to Compare Treatment on the Basis of Sentinel Node Biopsy Versus Neck Node Dissection in Operable T1-T2N0 Oral and Oropharyngeal Cancer. J Clin Oncol. 2020 Dec 1;38(34):4010-4018. doi: 10.1200/JCO.20.01661. Epub 2020 Oct 14.
Results Reference
derived
Learn more about this trial
Randomized, Open-label Economic and Medical Study on the Lymph Node Management of Squamous Cell Carcinoma of the Oral Cavity and Oropharynx Tumor Stage 1 or 2, Nodes 0 (T1-T2 N0) Operable
We'll reach out to this number within 24 hrs